BCMA/CD19 CAR T-Cell Therapy Against Antigen Escape
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple myeloma, particularly in refractory cases, are limited and often result in relapse due to heterogeneity of tumor cells and the hostile tumor microenvironment, leading to poor persistence and efficacy of CAR-T cell therapies.
Innovation Solution
Development of autologous BCMA/CD19 CAR T-cells that express a chimeric antigen receptor with specific binding domains for BCMA and CD19, combined in a single construct to enhance persistence and efficacy by targeting both antigens, administered in various doses to patients with refractory or relapsed multiple myeloma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemotherapy and single-target CAR-T therapy are used, then initial treatment response is achieved, but disease relapse occurs due to tumor heterogeneity and antigen escape
Solution Approach 1:
The patent combines multiple CAR-T cell products with different target antigens (BCMA, CD19, GPRC5D) into a sequential treatment regimen. This merging of multiple single-target therapies addresses tumor heterogeneity and prevents antigen escape by targeting multiple pathways simultaneously, thereby improving both treatment efficacy and extending remission duration in relapsed/refractory multiple myeloma patients
Solution Approach 2:
The treatment approach segments the therapy into distinct phases: initial BCMA CAR-T therapy, followed by CD19 CAR-T therapy upon relapse, and potentially GPRC5D CAR-T therapy as a third line. This segmentation allows each CAR-T product to be optimized for its specific target while collectively addressing the complexity of multiple myeloma through a structured, multi-stage treatment protocol
2Reliability
If high-dose chemotherapy and multiple drug classes are administered, then initial tumor control is achieved, but treatment toxicity and patient morbidity increase
Solution Approach 1:
The patent replaces conventional high-dose chemotherapy with immunotherapy-based CAR-T cell products. This substitution uses the patient's own modified immune cells to recognize and destroy tumor cells, achieving effective tumor control while avoiding the severe acute and long-term toxicities associated with high-dose chemotherapeutic agents like proteasome inhibitors and immunomodulatory drugs
3Reliability
If conventional therapy lines are progressed through, then initial responses are obtained, but disease becomes refractory with progressively shorter response periods
Solution Approach 1:
The patent changes the fundamental parameter of therapeutic mechanism by transitioning from chemotherapy-based treatment to CAR-T immunotherapy. This parameter change introduces a different mode of action that is not subject to the same resistance mechanisms, allowing patients who have progressed through multiple conventional therapy lines to achieve sustained responses with extended remission durations
Data Source
AI summary
The present disclosure relates to BCMA/CD19 CAR T-cell products and methods for treating relapsed or refractory BCMA+ or CD19+ malignancies.